Objective To explore the mechanism of Qizhi Tongqiao Capsule(QTC) in treating benign prostatic hyperplasia(BPH) and erectile dysfunction(ED) based on network pharmacology and molecular docking technology. Methods The active ingredients and corresponding targets of QTC were collected and obtained based on TCMSP, BATMAN, PubChem and Swiss Target Prediction databases, and the BPH and ED target genes were predicted by GeneCards database. The intersection targets were obtained by Venny 2.1, and the "drug component target disease" visual network diagram was constructed by Cytoscape 3.10.0. The protein interaction(PPI) network was constructed based on STRING database, and then imported into Cytoscape 3.10.0 to output the core targets, Metascape database for GO function and KEGG pathway enrichment analysis. Finally, molecular docking was carried out testing. Results A total of 70 active components of QTC were obtained, including crocetin, lycium barbarum alcohol, 3,9-di-o-methylnisolin, quercetin, kaempferol, etc; 146 "drug disease" intersection targets. QTC may act on multiple targets such as serine/threonine protein kinase 1 (AKT1), interleukin-6(IL6), estrogen receptor(ESR1), signal transducer and activator of transcription 3(STAT3), tumor necrosis factor (TNF), jun transcription factor (JUN), regulator of apoptosis (BCL2), caspase-3 (CASP3), and regulate NF-κB signaling, diabetic complications, calcium ion and other related signaling pathways. Molecular docking results showed that quercetin was well docked with the core target. Conclusion QTC may play a role in treating BPH and ED by regulating NF-κB signaling pathway, diabetes complications related pathway and calcium ion signaling pathway based on AKT1, IL6, ESR1, STAT3, TNF, JUN, BCL2, CASP3 and other targets, but it still needs to be verified in further research.